Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tezemlimogene daxadenorepvec
- Development stage
- Phase 1
- Lead developer
- DNAtrix
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intratumoral
01
Overview
DNX-2440 (tezemlimogene daxadenorepvec) is an armed oncolytic adenovirus engineered to selectively replicate in and destroy tumor cells. It incorporates the OX40 ligand (OX40L), a costimulatory molecule that enhances antitumor immune responses by stimulating T lymphocytes and acting as an OX40 receptor agonist. The virus also contains an integrin-binding RGD-4C motif for improved infectivity and can infect tumor cells independently of
- Other names
- tezemlimogene daxadenorepvecDNX-2440DNX2440DNX 2440Delta-24-RGDOXDelta24-RGDOXDelta 24-RGDOX
02
Targets
CD28 (Cluster of Differentiation 28)
Beyond the preview
Go deeper on tezemlimogene daxadenorepvec.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tezemlimogene daxadenorepvec.